324 related articles for article (PubMed ID: 31694864)
1. Complement Activation and Thrombotic Microangiopathies.
Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864
[TBL] [Abstract][Full Text] [Related]
2. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome.
Burwick RM; Feinberg BB
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1059-S1070. PubMed ID: 32986992
[TBL] [Abstract][Full Text] [Related]
3. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
[TBL] [Abstract][Full Text] [Related]
4. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome.
Vaught AJ; Gavriilaki E; Hueppchen N; Blakemore K; Yuan X; Seifert SM; York S; Brodsky RA
Exp Hematol; 2016 May; 44(5):390-8. PubMed ID: 26921648
[TBL] [Abstract][Full Text] [Related]
5. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
Kourouklaris A; Ioannou K; Athanasiou I; Panagidou A; Demetriou K; Zavros M
J Med Case Rep; 2014 Sep; 8():307. PubMed ID: 25219386
[TBL] [Abstract][Full Text] [Related]
6. An effective treatment of atypical hemolytic uremic syndrome with plasma exchange and eculizumab: A case report.
Sengul Samanci N; Ayer M; Ergen A; Ozturk S
Transfus Apher Sci; 2015 Jun; 52(3):314-6. PubMed ID: 25634788
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS-Case Report.
Lokki AI; Haapio M; Heikkinen-Eloranta J
Front Immunol; 2020; 11():548. PubMed ID: 32308654
[TBL] [Abstract][Full Text] [Related]
8. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
[TBL] [Abstract][Full Text] [Related]
9. [HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review].
Mancini A; Ardissino G; Angelini P; Giancaspro V; La Raia E; Nisi M; Proscia A; Tarantino G; Vitale O; D'elia F
G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983177
[TBL] [Abstract][Full Text] [Related]
10. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
Asif A; Nayer A; Haas CS
J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
[TBL] [Abstract][Full Text] [Related]
11. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.
Magro CM; Momtahen S; Mulvey JJ; Yassin AH; Kaplan RB; Laurence JC
Am J Dermatopathol; 2015 May; 37(5):349-56; quiz 357-9. PubMed ID: 25893747
[TBL] [Abstract][Full Text] [Related]
12. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab.
Riedl M; Hofer J; Giner T; Rosales A; Häffner K; Simonetti GD; Walden U; Maier T; Heininger D; Jeller V; Weiss G; van den Heuvel L; Zimmerhackl LB; Würzner R; Jungraithmayr TC
J Immunol Methods; 2016 Aug; 435():60-7. PubMed ID: 27238216
[TBL] [Abstract][Full Text] [Related]
13. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
[TBL] [Abstract][Full Text] [Related]
14. Modeling complement activation on human glomerular microvascular endothelial cells.
Stevens KH; Baas LM; van der Velden TJAM; Bouwmeester RN; van Dillen N; Dorresteijn EM; van Zuilen AD; Wetzels JFM; Michels MAHM; van de Kar NCAJ; van den Heuvel LP
Front Immunol; 2023; 14():1206409. PubMed ID: 37954621
[TBL] [Abstract][Full Text] [Related]
15. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E; Scully M; Ariceta G; Barbour T; Cataland S; Heyne N; Miyakawa Y; Ortiz S; Swenson E; Vallee M; Yoon SS; Kavanagh D; Haller H;
Kidney Int; 2020 Jun; 97(6):1287-1296. PubMed ID: 32299680
[TBL] [Abstract][Full Text] [Related]
16. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy.
Fakhouri F; Vercel C; Frémeaux-Bacchi V
Clin J Am Soc Nephrol; 2012 Dec; 7(12):2100-6. PubMed ID: 22879435
[TBL] [Abstract][Full Text] [Related]
17. Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation.
Stea ED; Skerka C; Accetturo M; Pesce F; Wiech T; Hartman A; Pontrelli P; Conserva F; Castellano G; Zipfel PF; Gesualdo L
Front Immunol; 2022; 13():1008294. PubMed ID: 36451836
[TBL] [Abstract][Full Text] [Related]
18. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Ariceta G; Dixon BP; Kim SH; Kapur G; Mauch T; Ortiz S; Vallee M; Denker AE; Kang HG; Greenbaum LA;
Kidney Int; 2021 Jul; 100(1):225-237. PubMed ID: 33307104
[TBL] [Abstract][Full Text] [Related]
19. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
[TBL] [Abstract][Full Text] [Related]
20. Hemolytic Uremic Syndrome in Pregnancy and Postpartum.
Bruel A; Kavanagh D; Noris M; Delmas Y; Wong EKS; Bresin E; Provôt F; Brocklebank V; Mele C; Remuzzi G; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1237-1247. PubMed ID: 28596415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
